Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis

Published:2021 Issue:1 Volume:27 Page:
ISSN:1087-2108
Container-title:Dermatology Online Journal
language:
Short-container-title:

Author:

Feldman Steven R,Zhang Jingchuan,Martinez Diane J,Lopez-Gonzalez Lorena,Hoit Marchlewicz Elizabeth,Shrady George,Mendelsohn Alan M,Zhao Yang

Publisher

California Digital Library (CDL)

Subject

Dermatology,General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States;Journal of Dermatological Treatment;2024-06-24

2. Advantages of IL-17 inhibitor, ixekizumab, in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2024-03-08

3. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan;Dermatology and Therapy;2023-11-29

4. Drug Utilization and Measurement of Medication Adherence: A Real World Study of Psoriasis in Italy;Pharmaceutics;2023-11-21

5. Real‐world drug survival of Brodalumab, in patients with psoriasis switched from Ixekizumab: Results of a single centre retrospective study (BroSwitch);JEADV Clinical Practice;2023-05-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP